UroGen Pharma Ltd.
URGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -17.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.1% | – | 88.5% | 89.9% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -93.8% | – | -192% | -107.8% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -121.3% | – | -216.5% | -152.7% |
| EPS Diluted | -0.69 | -1.05 | -0.92 | -0.8 |
| % Growth | 34.3% | -14.1% | -15% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |